July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli

July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va

HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R

BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal

On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent

May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa

BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.

April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de

April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie

A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of

The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and

On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen

Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi

During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p

Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C

Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, collaborating with IQVIA Brazil published an article on December 17 titled “

Beijing, China, December 24, 2021 – SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced resu